At a glance
ClinicalIndex Comparison RecordN/ACompleted· 149 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicentre, Non-interventional, Observational, Cohort Study to Evaluate the Long Term Clinical, Patient Reported and Health Care Resource Utilization Effects of an Early Response to Certolizumab Pegol (Cimzia®) in Rheumatoid Arthritis Patients in Daily Clinical Practice in the United Kingdom and Eire.
In Brief
An observational study for Arthritis,Rheumatoid. Completed, enrolled 149 participants across 22 sites in 2 countries.
Detailed Summary
To determine if early clinical response at 12 weeks to Certolizumab Pegol (CZP, Cimzia ®) therapy in adult Rheumatoid Arthritis (RA) patients is a predictor of better long term clinical response at 18 months compared with a lack of clinical response at 12 weeks.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis,Rheumatoid
CountriesIreland, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartJul 2011
Primary CompletionOct 2014
Study CompletionDec 2014
TodayJul 2026
First PostedFeb 2, 2011
Enrollment StartJul 1, 2011
Primary CompletionOct 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.4 years ago